• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2

    8/9/22 9:58:23 AM ET
    $BBQ
    $CRMD
    $FET
    $MEGL
    Restaurants
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBQ alert in real time by email

    U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

    Following the market opening Tuesday, the Dow traded up 0.06% to 32,853.24 while the NASDAQ fell 0.75% to 12,549.06. The S&P also fell, dropping, 0.14% to 4,134.32.

    Also check this: Tyson Foods, Take-Two Interactive And 3 Stocks To Watch Heading Into Monday


    Leading and Lagging Sectors


    Energy shares climbed 0.9% on Tuesday. Meanwhile, top gainers in the sector included W&T Offshore, Inc. (NYSE:WTI), up 19% and Forum Energy Technologies Inc (NYSE:FET) up 8%.


    In trading on Tuesday, information technology shares fell by 1.2%.


    Top Headline


    U.S. non-farm labor productivity declined an annualized 4.6% in the second quarter compared to market estimates of a 4.7% decline. Unit labor costs in the US nonfarm business sector, meanwhile, jumped by 10.8% in the second quarter, following a revised 12.7% increase in the prior period and versus analysts’ estimates of a 9.5% increase.


    Equities Trading UP


    Verona Pharma plc (NASDAQ:VRNA) shares shot up 99% to $13.85 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.


    Shares of BBQ Holdings, Inc. (NASDAQ:BBQ) got a boost, shooting 46% to $17.06 after the company announced MTY Food Group entered into a definitive merger agreement to acquire all of the outstanding shares of the company for $17.25 per share.


    Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares were also up, gaining 31% to $6.88. Mersana Therapeutics announced a global collaboration that provides GSK plc an exclusive option to co-develop and commercialize XMT-2056.


    Equities Trading DOWN

    Quanterix Corporation (NASDAQ:QTRX) shares tumbled 53% to $7.74 after the company announced Q2 results and provided an update on clinical development programs.


    Shares of CorMedix Inc. (NASDAQ:CRMD) were down 53% to $3.57 after the company announced it received a second Complete Response Letter from the FDA stating that the DefenCath NDA cannot be approved until certain deficiencies are resolved to the satisfaction of the FDA.


    Magic Empire Global Limited (NASDAQ:MEGL) was down, falling 55% to $53.04 on volatility following the company's IPO on Friday.

    Also check out: Traders More Optimistic After Better-Than-Expected Jobs Data


    Commodities

    In commodity news, oil traded up 1% to $91.66, while gold traded up 0.5% to $1,813.60.


    Silver traded down 0.1% to $20.59 on Tuesday while copper rose 0.9% to $3.6180.



    Euro zone


    European shares were mixed today. The eurozone’s STOXX 600 fell 0.5%, London’s FTSE 100 rose 0.3% while Spain’s IBEX 35 Index rose 0.5%. The German DAX fell 0.9%, French CAC 40 fell 0.3% and Italy’s FTSE MIB Index fell 0.6%.

    Retail sales in the UK climbed by 1.6% on a like-for-like basis for July from a year earlier, growing for the first time in five months.


    Economics

     

    The NFIB Small Business Optimism Index rose to 89.9 in July from 89.5 in June.


    U.S. non-farm labor productivity declined an annualized 4.6% in the second quarter compared to market estimates of a 4.7% decline. Unit labor costs in the US nonfarm business sector, meanwhile, jumped by 10.8% in the second quarter, following a revised 12.7% increase in the prior period and versus analysts’ estimates of a 9.5% increase.


    The Treasury is set to auction 52-week bills at 11:30 a.m. ET.


    The Treasury will auction 3-year notes at 1:00 p.m. ET.


    Check out this: Bitcoin, Ethereum Record Gains; Here Are The Top Crypto Movers For Monday


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 94,024,920 cases with around 1,059,210 deaths. India confirmed a total of at least 44,174,650 cases and 526,770 deaths, while France reported over 34,079,650 COVID-19 cases with 152,710 deaths. In total, there were at least 590,430,150 cases of COVID-19 worldwide with more than 6,439,010 deaths.

    Get the next $BBQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBQ
    $CRMD
    $FET
    $MEGL

    CompanyDatePrice TargetRatingAnalyst
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    Quanterix Corporation
    $QTRX
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    Verona Pharma plc
    $VRNA
    7/14/2025Buy → Neutral
    H.C. Wainwright
    Verona Pharma plc
    $VRNA
    7/1/2025$170.00Outperform
    Wolfe Research
    CorMedix Inc.
    $CRMD
    6/30/2025Buy → Hold
    D. Boral Capital
    CorMedix Inc.
    $CRMD
    6/30/2025$20.00Buy
    H.C. Wainwright
    Verona Pharma plc
    $VRNA
    4/28/2025$100.00Buy
    TD Cowen
    Verona Pharma plc
    $VRNA
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $BBQ
    $CRMD
    $FET
    $MEGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBQ
    $CRMD
    $FET
    $MEGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rowsey Paul E Iii was granted 8,557 shares (SEC Form 4)

    4 - FORUM ENERGY TECHNOLOGIES, INC. (0001401257) (Issuer)

    2/9/26 12:27:36 PM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    Chief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:06 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Todisco Joseph was granted 77,156 shares, increasing direct ownership by 11% to 774,749 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:03 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBQ
    $CRMD
    $FET
    $MEGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaplan Myron bought $275,500 worth of shares (25,000 units at $11.02), increasing direct ownership by 14% to 201,034 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    10/27/25 9:30:10 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO & President Krohn Tracy W bought $527,259 worth of shares (286,842 units at $1.84), increasing direct ownership by 37% to 1,060,198 units (SEC Form 4)

    4 - W&T OFFSHORE INC (0001288403) (Issuer)

    10/3/25 4:22:43 PM ET
    $WTI
    Oil & Gas Production
    Energy

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BBQ
    $CRMD
    $FET
    $MEGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cormedix upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Cormedix from Hold to Buy and set a new price target of $14.00

    10/20/25 9:02:46 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Quanterix from Buy to Hold and set a new price target of $5.00

    8/11/25 9:55:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Verona Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Verona Pharma from Buy to Neutral

    7/14/25 8:43:04 AM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBQ
    $CRMD
    $FET
    $MEGL
    SEC Filings

    View All

    Forum Energy Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - FORUM ENERGY TECHNOLOGIES, INC. (0001401257) (Filer)

    2/5/26 5:05:10 PM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Forum Energy Technologies Inc.

    SCHEDULE 13G - FORUM ENERGY TECHNOLOGIES, INC. (0001401257) (Subject)

    1/21/26 1:21:11 PM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    SEC Form 15-12G filed by Mersana Therapeutics Inc.

    15-12G - Mersana Therapeutics, Inc. (0001442836) (Filer)

    1/16/26 4:15:45 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBQ
    $CRMD
    $FET
    $MEGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CorMedix to Participate in Upcoming Investor Conferences

    BERKELEY HEIGHTS, N.J., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in March. Leerink Partners Global Healthcare ConferenceDate: March 10, 2026Time: 1:00pm EasternFormat: Fireside ChatWebcast: Link to webcast   Citizens Life Sciences ConferenceDate: March 11, 2026Time: 9:35am EasternFormat: Fireside ChatWebcast: Link to webcast   Barclays 28th Annual Global Healthcare ConferenceDate: Marc

    2/12/26 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FET Extends Credit Facility Maturity to February 2031

    Forum Energy Technologies, Inc. (NYSE:FET) announced today it has entered into an amendment to its senior secured asset-based lending credit facility ("Credit Facility"). Wells Fargo Bank, National Association, JPMorgan Chase Bank, N.A., and Bank of America, N.A., acted as joint lead arrangers and joint book runners. Wells Fargo Bank, National Association, will continue to act as the administrative agent. Lyle Williams, Executive Vice President and Chief Financial Officer, remarked, "This amendment further strengthens FET's balance sheet, and we appreciate our bank group's support. The Credit Facility commitments of $250 million provide significant flexibility for FET to fund strategic in

    2/4/26 5:19:00 PM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

    Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix's LucentAD® Complete LDT Quanterix Corporation (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for a multi-analyte algorithmic blood test for Alzheimer's disease (AD). This submission represents a significant milestone in the Company's mission to provide superior, non-invasive, high-performance diagnostic tools to aid in the evaluation of patients with cognitive symptoms for possible AD. The multi-analy

    2/3/26 8:33:00 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BBQ
    $CRMD
    $FET
    $MEGL
    Leadership Updates

    Live Leadership Updates

    View All

    Forum Energy Technologies Announces Appointment of The Honorable Leslie A. Beyer to its Board of Directors

    Forum Energy Technologies, Inc. (NYSE:FET) today announced the appointment of The Honorable Leslie A. Beyer to its Board of Directors. Ms. Beyer will also serve as a member of the Compensation & Human Capital Committee and the Nominating, Governance & Sustainability Committee. Ms. Beyer is the former Assistant Secretary of the Interior for Land and Minerals Management at the U.S. Department of Interior. Prior to that, Ms. Beyer served as Chief Executive Officer of the Energy Workforce and Technology Council (EWTC), the global energy technology and services association representing over 650,000 employees in the energy workforce. Before joining the EWTC, Ms. Beyer spent 15 years in Washingt

    1/12/26 8:00:00 AM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    CorMedix Therapeutics Announces Leadership and Board Updates

    BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. "Under t

    1/8/26 8:05:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBQ
    $CRMD
    $FET
    $MEGL
    Financials

    Live finance-specific insights

    View All

    Forum Energy Technologies Announces Timing of Fourth Quarter and Full Year 2025 Earnings Conference Call

    Forum Energy Technologies, Inc. (NYSE:FET) announced today that it will host its fourth quarter and full year 2025 earnings conference call at 10:00 a.m. Central Time on Friday, February 20, 2026. FET will issue a press release reporting its fourth quarter and full year 2025 earnings prior to the conference call. The call will be webcast through the Investor Relations link on FET's website at ir.f-e-t.com. Participants may also join the call by registering here. A replay of the call will be available on the Investor Relations website after the completion of the call at approximately 5:00 p.m. Central Time. FET is a global manufacturing company, serving the oil, natural gas, defense, and

    1/30/26 8:30:00 AM ET
    $FET
    Oil and Gas Field Machinery
    Consumer Discretionary

    Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

    Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 millionClosing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter e

    11/14/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBQ
    $CRMD
    $FET
    $MEGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

    SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/15/24 4:45:57 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    SC 13G/A - Verona Pharma plc (0001657312) (Subject)

    11/14/24 5:46:11 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 5:45:55 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care